pharmaphorum4d
Roche’s Herceptin/Perjeta combo product nears EU approval
Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...
pharmaphorum5d
Roche challenges NICE on Kadcyla and ignoring pricing deal
The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...
Top Analyst Reports for Roche, Comcast & Eaton
Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.
The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
Chugai Pharmaceuticals' World-Class Innovation Drives Strong Profitability Improvement
Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...
Nasdaq4d
The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries
Roche is also looking to diversify its portfolio in the wake of declining sales from legacy drugs (Avastin, Herceptin, MabThera and Actemra) due to competition from biosimilars. Roche has also ...